ImmunityBio and BeiGene partner on Phase III trial of NSCLC treatment combo

ImmunityBio has entered a supply agreement and partnership with BeiGene for conducting a confirmatory Phase III ResQ201A-NSCLC trial combining tislelizumab and Anktiva to treat advanced or metastatic non-small cell lung cancer (NSCLC) patients.